Balance Sheet

v3.25.2

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 2,211,575	$ 3,502,077
Unbilled receivable	1,204,979	124,115
Prepaid expenses and other current assets	1,865,041	1,718,490
Total current assets	5,281,595	5,344,682
Other assets	292,860	252,550
Total assets	5,574,455	5,597,232
Current liabilities:
Accounts payable	1,042,832	1,357,079
Accrued expenses and other liabilities	1,045,657	548,458
Notes payable and accrued interest	424,521	301,660
Total current liabilities	2,513,010	2,207,197
Long-term liabilities:
Other long-term liabilities	1,033	10,096
Total long-term liabilities	1,033	10,096
Total liabilities	2,514,043	2,217,293
Commitments and contingencies (Note 7)
Stockholders’ equity
Preferred stock, $0.0001 par value, 1,500,000 shares authorized, no shares issued and outstanding at June 30, 2025 and December 31, 2024
Common stock, $0.0001 par value, 250,000,000 shares authorized at June 30, 2025 and December 31, 2024; 2,393,262 and 1,355,779 shares issued at June 30, 2025 and December 31, 2024, respectively; 2,393,256 and 1,355,773 shares outstanding at June 30, 2025 and December 31, 2024, respectively	241	136
Additional paid-in capital	136,612,043	133,252,585
Accumulated deficit	(133,223,223)	(129,544,299)
Total Ensysce Biosciences, Inc. stockholders’ equity	3,389,061	3,708,422
Noncontrolling interests in stockholders’ deficit	(328,649)	(328,483)
Total stockholders’ equity	3,060,412	3,379,939
Total liabilities and stockholders’ equity	$ 5,574,455	$ 5,597,232

- Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

Source